Viking Therapeutics Inc — Cash Flow (NASDAQ:VKTX) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Cash from operating activities 21.78 M47.59 M48.4 M73.38 M87.79 M278.69 M 278.69 M Cash from investing activities 41.57 M37.96 M54.75 M179.09 M553.37 M341.39 M 341.39 M Cash from financing activities 950 K6.88 M4.16 M271.38 M612.46 M76.44 M 76.44 M Free cash flow 21.78 M47.59 M48.4 M73.38 M87.79 M278.69 M 278.69 M

Haberler

Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?

Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026

American Express, Oracle among market cap stock movers on Monday

Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin

Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough? (GPCR)

Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?

Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk

NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?

Viking Therapeutics: Full-Speed Ahead (NASDAQ:VKTX)

Viking: Buyers Quietly Accumulating On Obesity Drugs Launch Potential (NASDAQ:VKTX)

Cisco and Micron among market cap stock movers on Thursday

How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report